Key points are not available for this paper at this time.
Abstract Recombinant human epidermal growth factor (rhEGF) is widely utilized as an antiaging compound in wound‐healing therapies and cosmetic purposes. However, topical administration of rhEGF has limited treatment outcomes because of its poor percutaneous penetration and rapid proteinase degradation. To overcome these obstacles, this study aims to develop and characterize rhEGF‐containing conventional liposomes (rhEGF‐CLs) and transferosomes (rhEGF‐TFs) as efficient dermal carriers. Physicochemical characterization such as particle size, zeta potential (ZP), morphology, encapsulation efficiency (EE%), and release properties of nanocarriers as well as in vitro cytotoxicity in human dermal fibroblast (HDF) and human embryonic kidney (HEK293) cell lines were investigated. rhEGF‐TFs at the rhEGF concentration ranging from 0.05 to 1.0 μg/mL were chosen as the optimum formulation due to the desired release profile, acceptable EE%, optimal cell proliferation, and minimal cytotoxicity compared to the control and free rhEGF. However, higher concentrations caused a decrease in cell viability. The ratio 20:80 of Tween 80 to lipid was optimal for rhEGF‐TFs‐2, which had an average diameter of 233.23 ± 2.64 nm, polydispersity index of 0.33 ± 0.05, ZP of −15.46 ± 0.29 mV, and EE% of 60.50 ± 1.91. The formulations remained stable at 5°C for at least 1 month. TEM and SEM microscopy revealed that rhEGF‐TFs‐2 had a regular shape and unilamellar structure. In vitro drug release studies confirmed the superiority of rhEGF‐TFs‐2 in terms of optimal cumulative release of rhEGF approximately 82% within 24 h. Franz diffusion cell study showed higher rhEGF‐TFs‐2 skin permeation compared to free rhEGF solution. Taken together, we concluded that rhEGF‐TFs can be used as a promising formulation for wound healing and skin regeneration products.
Doust-Vaghe et al. (Tue,) studied this question.